ExpreS2ion Biotech Holding AB approved for listing on Nasdaq Stockholm First North

ExpreS2ion Biotech Holding AB ("ExpreS2ion ") announces that the Company has met the requirements for listing on Nasdaq Stockholm First North and today, July 27, it has received the stock exhange's formal approval. The first day of trading of ExpreS2ion’s shares is expected to be July 29, 2016.

CEO Steen Klysner comments
"In June we carried out a successful Initial Public Offering (IPO), which reflected the interest there is in ExpreS2ion. With the proceeds from the IPO, we can now continue to expand our marketing and sales efforts to enable a larger market penetration for our ExpreS2 platform."

Company description available
ExpreS2ions company description is available via the following link: http://www.expres2ionbio.com/files/bolagsbeskrivning.pdf

Financial Advisors and Certified Advisor

Sedermera Fondkommission is appointed as Certified Adviser for the Company.

For further information about ExpreS2ion, please contact:

Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

This press release contains information that ExpreS2ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 20.15 CET, July the 27th, 2016.

About ExpreS2ion

ExpreS2ion Biotech Holding AB, with company register number 559033-3729, has through the wholly owned Danish subsidiary ExpreS2ion Biotechnologies ApS, developed a platform technology enabling cost effective and robust production of complex proteins for the development of vaccines and diagnostics for e.g. Malaria and Zika. Since foundation in 2010, the subsidiary has used its patented ExpreS2 platform to produce more than 200 proteins in collaboration with research institutions and biopharmaceutical companies, with an efficiency and success rate superior to competing technologies.


About Us

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS2, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops novel VLP based vaccines through the joint venture AdaptVac ApS, which was founded in 2017.